This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Accelerate oligonucleotide and peptide products from early discovery to late-stage development & commercialization.

A look back at TIDES Asia Virtual Scientific Forum 2021

Share this article

On Mar 2 – 5, 2021, TIDES Asia made its debut as a Virtual Scientific Forum, with a series of live and recorded webinars, presented by industry experts, screened across the week.

Over 700 industry professionals registered to watch the webinars online over the course of the week, which explored topics across discovery, CMC and development of peptide, oligonucleotide, mRNA and genome edited therapeutics.

In this report, we review the hottest webinars at the TIDES Asia Virtual Scientific Forum 2021, including the latest work in antisense technology, mRNA-based vaccines, novel, modular GalNAc access and peptide drug discovery and development.

Click the image at the top of the page or here to explore the report.

The report includes:

  • How Antisense Drugs Work: Molecular Mechanisms of Cellular Pharmacokinetics, Pharmacodynamis and Toxicity
  • N-Lorem a New Charitable Foundation: Creating Individualized Treatments for Patients with Ultra-Rare Diseases using Antisense
  • LGC’s Development of a Novel, Modular, GalNAc Access, and Conjugation Strategies for Nucleic Acid Medicines
  • A Strategic Vision for Therapeutic Development: The PeptiDream Story
  • RNA Therapeutics: Importance of Nucleotide Sequence and Modifications on the Mechanism of Action
  • Update: Usage of an mRNA Platform Technology for “Light Speed” Development of a Vaccine against SARS-CoV-2

Click the image at the top of the page or here to explore the report.

Share this article

Upcoming event

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

14 - 16 Sep 2022, Kyoto, Japan
Industry leaders and service providers share cutting-edge content and company expertise across the Oligonucleotide, Peptide, mRNA and Drug Delivery spectrum
Go to site